Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 285 entries
View as:

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT03099330 Org: User:
Start: 07/19/17 End: 12/31/18 Due: 12/31/19

A Phase II Study of Anlotinib in MTC Patients

Phase: N/A Priority: Normal
NCT ID: NCT01874873 Org: User:
Start: 04/30/13 End: 12/31/16 Due: 12/31/17

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT05068921 Org: User:
Start: 12/09/21 End: 07/31/23 Due: 07/31/24

Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05834543 Org: User:
Start: 05/26/23 End: 12/31/24 Due: 12/31/25

A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

Phase: N/A Priority: Normal
NCT ID: NCT06326671 Org: User:
Start: 02/28/24 End: 04/30/24 Due: 04/30/25

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Phase: N/A Priority: Normal
NCT ID: NCT06245941 Org: User:
Start: 05/13/24 End: 05/31/27 Due: 05/31/28

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05365178 Org: User:
Start: 07/01/22 End: 06/30/26 Due: 06/30/27

A Study of Anlotinib in Subjects With Advanced Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT04216082 Org: User:
Start: 08/01/13 End: 08/01/15 Due: 08/01/16

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04203719 Org: User:
Start: 05/09/20 End: 05/30/21 Due: 05/30/22

Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT03777085 Org: User:
Start: 01/10/19 End: 12/30/20 Due: 12/30/21

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Phase: N/A Priority: Normal
NCT ID: NCT03771781 Org: User:
Start: 04/16/18 End: 05/25/18 Due: 05/25/19

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06408285 Org: User:
Start: 05/22/24 End: 08/19/24 Due: 08/19/25

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04439890 Org: User:
Start: 08/08/19 End: 12/31/21 Due: 12/31/22

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

Phase: N/A Priority: Normal
NCT ID: NCT05292196 Org: User:
Start: 05/20/22 End: 12/05/23 Due: 12/05/24

Tolerance and Pharmacokinetics of TQB2450

Phase: N/A Priority: Normal
NCT ID: NCT03460457 Org: User:
Start: 03/15/18 End: 03/15/19 Due: 03/15/20

Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT05487976 Org: User:
Start: 04/28/22 End: 04/30/23 Due: 04/30/24

A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）

Phase: N/A Priority: Normal
NCT ID: NCT04326348 Org: User:
Start: 07/17/20 End: 07/31/22 Due: 07/31/23

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06126562 Org: User:
Start: 10/31/23 End: 12/15/23 Due: 12/15/24

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04805060 Org: User:
Start: 04/23/21 End: 12/12/25 Due: 12/12/26

A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT04955834 Org: User:
Start: 07/27/21 End: 12/31/25 Due: 12/31/26

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04073550 Org: User:
Start: 10/31/19 End: 07/31/22 Due: 07/31/23

Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05815862 Org: User:
Start: 02/15/23 End: 12/31/24 Due: 12/31/25

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04804904 Org: User:
Start: 05/20/21 End: 07/03/21 Due: 07/03/22

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Phase: N/A Priority: Normal
NCT ID: NCT01924195 Org: User:
Start: 08/31/13 End: 10/31/15 Due: 10/31/16

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Phase: N/A Priority: Normal
NCT ID: NCT05481645 Org: User:
Start: 08/22/22 End: 12/31/24 Due: 12/31/25